Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00956163 · ClinicalTrials.gov registry record · Early Phase 1
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer
A Early Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT00956163: Completed Early Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00956163 is a Early Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00956163, a Early Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase 0 trial studies whole body fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) scan and whole body magnetic resonance imaging (MRI) in finding bone metastases in patients with prostate cancer. Diagnostic procedures, such as whole body fluorine F 18 sodium fluoride PET/CT scan and whole body MRI, may help find and diagnose bone metastases.
Interventions
- PROCEDURE positron emission tomography
- PROCEDURE computed tomography
- PROCEDURE magnetic resonance imaging
- RADIATION fluorine F 18 sodium fluoride
- RADIATION technetium Tc 99m methylene diphosphonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00956163
The ClinicalTrials.gov registry entry for NCT00956163 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which positron emission tomography is the first listed.
NCT00956163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00956163 about?
NCT00956163 is a clinical study titled "Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer". This phase 0 trial studies whole body fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) scan and whole body magnetic resonance imaging (MRI) in finding bone metastases in patients with prostate cancer. Diagnostic procedures, such as whole body fluorine F 18 so...
What is the current status of trial NCT00956163?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2010-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00956163?
The interventions under investigation include: positron emission tomography (PROCEDURE), computed tomography (PROCEDURE), magnetic resonance imaging (PROCEDURE), fluorine F 18 sodium fluoride (RADIATION), technetium Tc 99m methylene diphosphonate (RADIATION).
Who is sponsoring clinical trial NCT00956163?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.